Good morning! And welcome back.
For a list of results and economic announcements due this week, please check out The Week Ahead (published on Friday).
Today's Agenda is complete.
12.30pm: wrapping it up there for today, cheers!
Companies Reporting
Name (Mkt Cap) | RNS | Summary | Our view (Author) |
---|---|---|---|
Diageo (LON:DGE) (£47.9bn) | Q3 net sales +2.9%, organically +5.9%. FY25 guidance unchanged. Tariff impact c.$150m. | AMBER (Graham) I'm downgrading this one notch today, as the company hasn't quite done enough to keep me on board with a moderately positive view. Higher than target leverage is the straw that breaks the analyst's back. | |
Assura (LON:AGR) / Primary Health Properties (LON:PHP) | KKR/Stonepeak argues that its bid for AGR is superior to Friday’s increased offer from PHP. | ||
Genuit (LON:GEN) (£1.0bn) | YTD revenue +8.5%. Trading in line with expectations, FY outlook maintained. | ||
Kainos (LON:KNOS) (£997m) | In line. Revenue -4%, adj PBT -15% to £65.6m. FY25 bookings -10% to £382.4m. £30m buyback. | AMBER (Roland) Today’s results are in line with reduced expectations following last year’s profit warning. While the balance sheet remains strong and cash generation is good, major restructuring and a rather mixed outlook leave me feeling that there’s still some uncertainty about the year ahead. With the stock still trading close to 20x forecast earnings, I’m staying neutral at this point. | |
Harworth (LON:HWG) (£554m) | “Significant progress” on major sites, improved residential affordability in Yorkshire/Midlands. | ||
Cerillion (LON:CER) (£541m) | Rev -7%, recurring rev +8%. Adj PBT -12% to £9.3m. Backlog +7%. “Well positioned” for FY targets. | AMBER (Roland) H1 results show a fall in profits, but broker forecasts are unchanged and new contract wins seem promising. The H2 weighting to earnings appears to be covered by new contracts, but FY25 earnings are still expected to be flat vs FY24. Given the demanding valuation and 45/55 H2 earnings weighting, I’m staying neutral at this time. | |
Mobico (LON:MCG) (£170m) | Q1 rev +9%, ALSA strong, UK/DE turnaround continues. NAm sale on track. £25m cost savings. | RED (Graham) I have my doubts as to whether this would be an attractive investment opportunity even if its balance sheet had already been repaired. Given the recent disappointment and ongoing struggles, I'll leave it RED for now. | |
Camellia (LON:CAM) (£139m) |